Tenet Healthcare (NYSE:THC) Releases FY 2025 Earnings Guidance

Tenet Healthcare (NYSE:THC - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 11.990-13.120 for the period, compared to the consensus earnings per share estimate of 12.200. The company issued revenue guidance of $20.6 billion-$21.0 billion, compared to the consensus revenue estimate of $20.9 billion.

Tenet Healthcare Trading Up 2.0 %

Shares of NYSE:THC traded up $2.92 during trading on Friday, reaching $148.21. The stock had a trading volume of 1,467,131 shares, compared to its average volume of 1,559,298. Tenet Healthcare has a fifty-two week low of $109.82 and a fifty-two week high of $171.20. The business has a fifty day moving average price of $127.09 and a 200-day moving average price of $136.47. The stock has a market cap of $13.99 billion, a P/E ratio of 4.60, a PEG ratio of 1.02 and a beta of 1.77. The company has a quick ratio of 1.70, a current ratio of 1.78 and a debt-to-equity ratio of 2.25.

Tenet Healthcare (NYSE:THC - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $4.36 earnings per share for the quarter, topping analysts' consensus estimates of $3.11 by $1.25. The company had revenue of $5.22 billion for the quarter, compared to analyst estimates of $5.15 billion. Tenet Healthcare had a return on equity of 21.88% and a net margin of 15.48%. The business's revenue for the quarter was down 2.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.22 EPS. As a group, analysts anticipate that Tenet Healthcare will post 12.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on THC shares. StockNews.com raised shares of Tenet Healthcare from a "hold" rating to a "buy" rating in a research report on Thursday. UBS Group boosted their price objective on shares of Tenet Healthcare from $217.00 to $230.00 and gave the company a "buy" rating in a research note on Wednesday. Morgan Stanley assumed coverage on Tenet Healthcare in a report on Wednesday, March 26th. They issued an "overweight" rating and a $165.00 target price on the stock. Truist Financial cut their price objective on Tenet Healthcare from $190.00 to $175.00 and set a "buy" rating on the stock in a report on Monday, January 6th. Finally, TD Cowen started coverage on shares of Tenet Healthcare in a research report on Wednesday, February 26th. They set a "buy" rating and a $175.00 target price for the company. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $172.19.

Insider Activity

In other Tenet Healthcare news, Director J Robert Kerrey sold 9,525 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $125.43, for a total transaction of $1,194,720.75. Following the completion of the sale, the director now directly owns 27,378 shares in the company, valued at approximately $3,434,022.54. This trade represents a 25.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.81% of the stock is owned by company insiders.

About Tenet Healthcare

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.